Novartis has entered a research and licensing agreement worth up to $1.8 billion with Unnatural Products to develop oral peptide medicines targeting cardiovascular disease using macrocyclic peptide technology.
Novartis has signed a research partnership and licensing agreement with Unnatural Products valued at up to $1.8 billion to develop macrocyclic peptide therapeutics targeting cardiovascular diseases using AI-driven drug discovery.
Unnatural Products entered a research collaboration and licensing agreement with Novartis worth up to $1.8 billion to develop orally-delivered macrocyclic peptide therapeutics for an undisclosed cardiovascular program.
